Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives $35.70 Average Price Target from Analysts

Definium Therapeutics, Inc. (NASDAQ:DFTX) has received an average recommendation of “Buy” from the twelve analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $35.70.

Several research firms have weighed in on DFTX. Robert W. Baird set a $37.00 price target on Definium Therapeutics in a research report on Thursday, January 29th. Chardan Capital raised Definium Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Royal Bank Of Canada raised their target price on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. HC Wainwright boosted their target price on shares of Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Definium Therapeutics in a research report on Monday, February 2nd.

Definium Therapeutics Price Performance

NASDAQ:DFTX opened at $18.06 on Wednesday. Definium Therapeutics has a 52-week low of $4.70 and a 52-week high of $19.62. The company has a market cap of $1.78 billion, a P/E ratio of -8.48 and a beta of 2.56. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.29 and a current ratio of 6.29. The stock’s 50-day simple moving average is $16.58 and its 200 day simple moving average is $13.42.

Insider Transactions at Definium Therapeutics

In related news, CEO Robert Barrow sold 25,791 shares of Definium Therapeutics stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $339,151.65. Following the completion of the transaction, the chief executive officer owned 778,477 shares in the company, valued at approximately $10,236,972.55. This trade represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Daniel Karlin sold 5,600 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $73,640.00. Following the transaction, the insider directly owned 425,025 shares in the company, valued at approximately $5,589,078.75. This trade represents a 1.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 42,667 shares of company stock worth $561,071 in the last ninety days. Insiders own 2.26% of the company’s stock.

Institutional Trading of Definium Therapeutics

A number of hedge funds have recently made changes to their positions in the business. CenterBook Partners LP acquired a new position in shares of Definium Therapeutics during the 3rd quarter worth approximately $1,880,000. Marshall Wace LLP lifted its holdings in Definium Therapeutics by 31.9% during the 2nd quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock valued at $22,204,000 after purchasing an additional 828,067 shares during the last quarter. Royce & Associates LP acquired a new stake in Definium Therapeutics during the 3rd quarter valued at $955,000. Boxer Capital Management LLC bought a new position in Definium Therapeutics during the third quarter worth $1,928,000. Finally, Geode Capital Management LLC boosted its position in Definium Therapeutics by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock worth $11,252,000 after purchasing an additional 66,663 shares during the period. 27.91% of the stock is owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.